Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMINGO: GLPG2222 in CF Homozygous F508del
NCT03119649Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of galicaftor in cystic fibrosis (CF), sponsored by Galapagos NV. Started Mar 2017; status: completed.
02
Drugs
galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03119649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119649.